Randomized trial demonstrates ultrasensitive CK-MB detection in point-of-care settings, suggesting a new approach for heart attack diagnosis.
The early and accurate diagnosis of acute myocardial infarction (AMI) depends on the sensitive detection of the cardiac biomarker Creatine Kinase MB isoenzyme (CK-MB). However, conventional immunoassays still suffer from limited sensitivity and speed for practical point-of-care testing.Herein, we report a novel surface-enhanced Raman scattering (SERS) immunosensing platform based on the functional integration of pre-synthesized nanomaterials. The key innovation lies in a “sandwich-on-substrate” architecture, in which the classic sandwich immunocomplex is concentrated and immobilized onto a flexible, jellyfish-like gold nanowire (AuNW) film.This design enables strong plasmonic coupling between the AuNW substrate and SERS-active Ag–Au core–shell nanoflower (BCSNF) tags, providing more than one order-of-magnitude signal enhancement over conventional formats.The integrated platform exhibits excellent analytical performance toward CK-MB detection, with a wide linear range, a high correlation coefficient (R² = 0.990), and a low detection limit of 0.076 ng/mL.This work demonstrates that rational integration of high-performance nanomaterials—rather than complex de novo synthesis—represents a reliable and efficient strategy for constructing advanced biosensors, paving the way for the development of next-generation ultrasensitive point-of-care diagnostic devices.
No takes yet. Share an insight, caveat, or question.
Z H Chen (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: